Epigenetic drugs as immunomodulators for combination therapies in solid tumors

The language of covalent histone modifications

Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679 · see citing works

Immunogenic Cell Death in Cancer Therapy

Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · see citing works

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Minucci, S., & Pelicci, P. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1779 · Cited by 2,211 · see citing works

The Polycomb group protein EZH2 directly controls DNA methylation

Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204 · see citing works

The epigenetic progenitor origin of human cancer

Feinberg, A. P., OHLSSON, R. I., & Henikoff, S. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,851 · see citing works

DNA methylation in cancer: too much, but also too little

Ehrlich, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205651 · Cited by 1,540 · see citing works

FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma

Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365 · see citing works

Suv39h-Mediated Histone H3 Lysine 9 Methylation Directs DNA Methylation to Major Satellite Repeats at Pericentric Heterochromatin

Lehnertz, B., Ueda, Y., Derijck, A. A. H. A., Braunschweig, U., Perez-Burgos, L., Kubicek, S., Chen, T., Li, E., Jenuwein, T., & Peters, A. H. F. M. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00432-9 · Cited by 1,248 · see citing works

Cancer epigenetics reaches mainstream oncology

Rodríguez‐Paredes, M., & Esteller, M. (2011) · Nature Medicine · doi:10.1038/nm.2305 · Cited by 1,207 · see citing works

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,198 · see citing works

The epigenotype

Waddington, C. H. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dyr184 · Cited by 1,082 · see citing works

Dna Hypomethylation In Cancer Cells

Ehrlich, M. (2009) · Epigenomics · doi:10.2217/epi.09.33 · Cited by 1,065 · see citing works

Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines.

Fang, M., Wang, Y., Ai, N., Hou, Z., Sun, Y., Lu, H., Welsh, W. J., & Yang, C. S. (2003) · PubMed · Cited by 1,049 · see citing works

Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9Preprint

Tachibana, M., Ueda, J., Fukuda, M., Takeda, N., Ohta, T., Iwanari, H., Sakihama, T., Kodama, T., Hamakubo, T., & Shinkai, Y. (2005) · Genes & Development · doi:10.1101/gad.1284005 · Cited by 853 · see citing works

The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation

Wang, J., Hevi, S., Kurash, J. K., Lei, H., Gay, F., Bajko, J., Su, H., Sun, W., Chang, H., Xu, G., et al. (2008) · Nature Genetics · doi:10.1038/ng.268 · Cited by 827 · see citing works

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1

Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C. E. A., Callegari, E., Schwind, S., Pang, J., Yu, J., Muthusamy, N., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170589 · Cited by 781 · see citing works

Histone H3 Lysine 9 Methylation and HP1γ Are Associated with Transcription Elongation through Mammalian Chromatin

Vakoc, C. R., Mandat, S. A., Olenchock, B. A., & Blobel, G. A. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.011 · Cited by 698 · see citing works

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

Knutson, K. L., & Disis, M. L. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0653-2 · Cited by 689 · see citing works

NK cells and cancer immunosurveillance

Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682 · see citing works

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.

Jüttermann, R., Li, E., & Jaenisch, R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.11797 · Cited by 679 · see citing works

bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia

Hanada, M., Delia, D., Aiello, A., Stadtmauer, E. A., & Reed, J. (1993) · Blood · doi:10.1182/blood.v82.6.1820.1820 · Cited by 673 · see citing works

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

Sharma, P., Wagner, K., Wolchok, J. D., & Allison, J. P. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3153 · Cited by 639 · see citing works

DNA Methylation Is the Primary Silencing Mechanism for a Set of Germ Line- and Tumor-Specific Genes with a CpG-Rich Promoter

Smet, C. D., Lurquin, C., Lethé, B., Martelange, V., & Boon, T. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.11.7327 · Cited by 598 · see citing works

Epigenetic Reactivation of Tumor Suppressor Genes by a Novel Small-Molecule Inhibitor of Human DNA Methyltransferases

Brueckner, B., Boy, R. G., Siedlecki, P. S., Musch, T., Kliem, H., Zielenkiewicz, P., Suhai, S., Wießler, M., & Lyko, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2957 · Cited by 548 · see citing works

The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.

Smet, C. D., Backer, O. D., Faraoni, I., Lurquin, C., Brasseur, F., & Boon, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.7149 · Cited by 542 · see citing works

Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis

Stingl, J., & Caldas, C. (2007) · Nature Reviews. Cancer · doi:10.1038/nrc2212 · Cited by 518 · see citing works

Functional Diversity of DNA Methyltransferase Inhibitors in Human Cancer Cell Lines

Stresemann, C., Brueckner, B., Musch, T., Stopper, H., & Lyko, F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2821 · Cited by 385 · see citing works

The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

Fratta, E., Coral, S., Covre, A., Parisi, G., Colizzi, F., Danielli, R., Nicolay, H. J. M., Sigalotti, L., & Maio, M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.02.001 · Cited by 371 · see citing works

(-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells

Nandakumar, V., Vaid, M., & Katiyar, S. K. (2011) · Carcinogenesis · doi:10.1093/carcin/bgq285 · Cited by 370 · see citing works

Natural Killer Cell–Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate

Armeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4252 · Cited by 359 · see citing works

Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice

Howard, G., Eiges, R., Gaudet, F., Jaenisch, R., & Eden, A. (2007) · Oncogene · doi:10.1038/sj.onc.1210631 · Cited by 341 · see citing works

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

Goodyear, O. C., Agathanggelou, A., Novitzky‐Basso, I., Siddique, S., McSkeane, T., Ryan, G. B., Vyas, P., Cavenagh, J. D., Stankovic, T., Moss, P. A. H., et al. (2010) · Blood · doi:10.1182/blood-2009-11-249474 · Cited by 340 · see citing works

Epigenetic Regulation by Histone Methylation and Histone Variants

Cheung, P., & Lau, P. N. I. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0496 · Cited by 329 · see citing works

Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells

Estève, P., Chin, H. G., Benner, J. S., Feehery, G. R., Samaranayake, M., Horwitz, G. A., Jacobsen, S. E., & Pradhan, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810362106 · Cited by 319 · see citing works

Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.

Weber, J. S., Salgaller, M. L., Samid, D., Johnson, B., Herlyn, M., Lassam, N. J., Treisman, J. S., & Rosenberg, S. A. (1994) · PubMed · Cited by 295 · see citing works

Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors

Magner, W. J., Kazim, A. L., Stewart, C., Romano, M. A., Catalano, G., Grande, C., Keiser, N., Santaniello, F., & Tomasi, T. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7017 · Cited by 294 · see citing works

Molecular Coupling of DNA Methylation and Histone Methylation

Hashimoto, H., Vertino, P. M., & Cheng, X. (2010) · Epigenomics · doi:10.2217/epi.10.44 · Cited by 287 · see citing works

Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma.

Mittelman, A., Chen, Z. J., Yang, H., Wong, G. Y., & Ferrone, S. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.2.466 · Cited by 260 · see citing works

Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3–Dependent Expression of MHC Class I–Related Chain A and B

Skov, S., Pedersen, M. T., Andresen, L. O., Straten, P. T., Woetmann, A., & Ødum, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0599 · Cited by 260 · see citing works

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2?-deoxycytidine treatment

Serrano, A., Tanzarella, S., Lionello, I., Méndez, R., Traversari, C., Ruiz‐Cabello, F., & Garrido, F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1452 · Cited by 239 · see citing works

Trials with ‘epigenetic’ drugs: An update

Nebbioso, A., Carafa, V., Benedetti, R., & Altucci, L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.004 · Cited by 237 · see citing works

Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura

Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Pishchik, V., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0669 · Cited by 227 · see citing works

Translating Tumor Antigens into Cancer Vaccines

Buonaguro, L., Petrizzo, A., Tornesello, M. L., & Buonaguro, L. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00286-10 · Cited by 220 · see citing works

Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine

Sigalotti, L., Fratta, E., Coral, S., Tanzarella, S., Danielli, R., Colizzi, F., Fonsatti, E., Traversari, C., Altomonte, M., & Maio, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1442 · Cited by 218 · see citing works

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

Shen, L., Ciesielski, M. J., Ramakrishnan, S., Miles, K. M., Ellis, L., Sotomayor, P. C., Shrikant, P. A., Fenstermaker, R. A., & Пили, Р. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030815 · Cited by 205 · see citing works

DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas

Nie, Y. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1615 · Cited by 203 · see citing works

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

Khan, A. N. H., Gregorie, C. J., & Tomasi, T. B. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0402-4 · Cited by 197 · see citing works

Epigenetic regulation of MHC-II and CIITA genes

Wright, K. L., & Ting, J. P.-Y. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.07.007 · Cited by 194 · see citing works

Promoter Demethylation and Histone Acetylation Mediate Gene Expression of MAGE-A1, -A2, -A3, and -A12 in Human Cancer Cells

Wischnewski, F., Pantel, K., & Schwarzenbach, H. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0229 · Cited by 185 · see citing works

Cytotoxic CD4 T Cells in Antiviral Immunity

Marshall, N. B., & Swain, S. L. (2011) · BioMed Research International · doi:10.1155/2011/954602 · Cited by 184 · see citing works

The role of classical and non-classical HLA class I antigens in human tumors

Bukur, J., Jasinski‐Bergner, S., & Seliger, B. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.03.003 · Cited by 175 · see citing works

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

Wolchok, J. D., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Chin, K. M., Cykowski, L., de Pril, V., Humphrey, R. W., & Lebbé, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt161 · Cited by 175 · see citing works

Romidepsin: a novel histone deacetylase inhibitor for cancer

Bertino, E. M., & Otterson, G. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594437 · Cited by 169 · see citing works

Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma

Schulz, W. A., Elo, J. P., Florl, A. R., Pennanen, S., Santourlidis, S., Engers, R., Buchardt, M., Seifert, H., & Visakorpi, T. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10092 · Cited by 165 · see citing works

Molecular mechanisms of MHC class I abnormalities and APM components in human tumors

Seliger, B. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0515-4 · Cited by 156 · see citing works

Bortezomib and Depsipeptide Sensitize Tumors to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand: A Novel Method to Potentiate Natural Killer Cell Tumor Cytotoxicity

Lundqvist, A., Abrams, S. I., Schrump, D. S., Alvarez, G., Suffredini, D. A., Berg, M., & Childs, R. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0680 · Cited by 145 · see citing works

5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.

Coral, S., Sigalotti, L., Altomonte, M., Engelsberg, A., Colizzi, F., Cattarossi, I., Maraskovsky, E., Jäger, E., Seliger, B., & Maio, M. (2002) · PubMed · Cited by 143 · see citing works

Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications

Sigalotti, L., Fratta, E., Coral, S., Cortini, E., Covre, A., Nicolay, H. J. M., Anzalone, L., Pezzani, L., Giacomo, A. M. D., Fonsatti, E., et al. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21066 · Cited by 142 · see citing works

Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824

Vo, D. D., Prins, R. M., Begley, J. L., Donahue, T. R., Morris, L. F., Bruhn, K. W., de la Rocha, P., Yang, M.-Y., Mok, S., Garbán, H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1456 · Cited by 137 · see citing works

De novoInduction of a Cancer/Testis Antigen by 5-Aza-2′-Deoxycytidine Augments Adoptive Immunotherapy in a Murine Tumor Model

Guo, Z. S., Hong, J. A., Irvine, K. R., Chen, G. A., Spiess, P. J., Liu, Y., Zeng, G., Wunderlich, J. R., Nguyen, D. M., Restifo, N. P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3020 · Cited by 137 · see citing works

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 Mg/Kg within an expanded access programme

Di Giacomo, A. M., Calabrò, L., Danielli, R., Fonsatti, E., Bertocci, E., Pesce, I., Fazio, C., Cutaia, O., Giannarelli, D., Miracco, C., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1418-6 · Cited by 135 · see citing works

Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells

Fiegler, N., Textor, S., Arnold, A., Rölle, A., Oehme, I., Breuhahn, K., Moldenhauer, G., Witzens‐Harig, M., & Cerwenka, A. (2013) · Blood · doi:10.1182/blood-2013-02-482513 · Cited by 135 · see citing works

Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma

Gollob, J., Sciambi, C. J., Peterson, B. L., Richmond, T. M., Thoreson, M., Moran, K., Dressman, H. K., Jelı́nek, J., & Issa, J. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0883 · Cited by 132 · see citing works

Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

Fonsatti, E., Nicolay, H. J. M., Sigalotti, L., Calabrò, L., Pezzani, L., Colizzi, F., Altomonte, M., Guidoboni, M., Marincola, F. M., & Maio, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3091 · Cited by 131 · see citing works

Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR)

Coral, S., Sigalotti, L., Gasparollo, A., Cattarossi, I., Visintin, A., Cattelan, A., Altomonte, M., & Maio, M. (1999) · Journal of Immunotherapy · doi:10.1097/00002371-199901000-00003 · Cited by 127 · see citing works

Overcoming Resistance to Interferon-Induced Apoptosis of Renal Carcinoma and Melanoma Cells by DNA Demethylation

Reu, F. J., Bae, S. I., Cherkassky, L., Leaman, D. W., Lindner, D. J., Beaulieu, N., MacLeod, A. R., & Borden, E. C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4074 · Cited by 125 · see citing works

HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer

López‐Soto, A., Folgueras, A. R., Seto, E., & Gonzalez, S. R. (2009) · Oncogene · doi:10.1038/onc.2009.117 · Cited by 118 · see citing works

Epigenetic regulation of immune escape genes in cancer

Tomasi, T. B., Magner, W. J., & Khan, A. N. H. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0164-4 · Cited by 117 · see citing works

Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous Melanoma

Sigalotti, L., Coral, S., Nardi, G., Spessotto, A., Cortini, E., Cattarossi, I., Colizzi, F., Altomonte, M., & Maio, M. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200201000-00002 · Cited by 114 · see citing works

Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies

Christiansen, A. J., West, A. C., Banks, K.-M., Haynes, N. M., Teng, M. W. L., Smyth, M. J., & Johnstone, R. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011037108 · Cited by 113 · see citing works

Inhibition of Histone Lysine Methylation Enhances Cancer–Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer

Rao, M., Chinnasamy, N., Hong, J. A., Zhang, Y., Zhang, M. F., Xi, S., Liu, F., Márquez, V. E., Morgan, R. A., & Schrump, D. S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2442 · Cited by 111 · see citing works

Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer

Woloszynska‐Read, A., Mhawech-Fauceglia, P. Y., Yu, J., Odunsi, K. O., & Karpf, A. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5279 · Cited by 110 · see citing works

Promoter methylation of cyclin D2 gene in gastric carcinoma

Oshimo, Y., Nakayama, H., Ito, R., Kitadai, Y., Yoshida, K., Chayama, K., & Yasui, W. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.6.1663 · Cited by 109 · see citing works

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

Sigalotti, L., Covre, A., Fratta, E., Parisi, G., Colizzi, F., Rizzo, A., Danielli, R., Nicolay, H. J. M., Coral, S., & Maio, M. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-56 · Cited by 108 · see citing works

Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-γ-induced HLA-DR expression in colorectal and gastric cancer cells

Satoh, A., Toyota, M., Ikeda, H., Morimoto, Y., Akino, K., Mita, H., Suzuki, H., Sasaki, Y., Kanaseki, T., Takamura, Y., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1208144 · Cited by 105 · see citing works

Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules

Adair, S. J., & Hogan, K. T. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0582-6 · Cited by 104 · see citing works

MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing

Bao, L., DUNHAM, K. R., & Lucas, K. G. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1037-z · Cited by 87 · see citing works

A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia

Klisovic, R. B., Stock, W., Cataland, S. R., Klisovic, M. I., Liu, S., Blum, W. G., Green, M., Odenike, O. M., Godley, L. A., Burgt, J. A. V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1320 · Cited by 87 · see citing works

Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B‐cell lymphoma

Cycon, K. A., Mulvaney, K. M., Rimsza, L. M., Persky, D. O., & Murphy, S. P. (2013) · Immunology · doi:10.1111/imm.12136 · Cited by 83 · see citing works

Decitabine and Vorinostat Cooperate To Sensitize Colon Carcinoma Cells to Fas Ligand-Induced Apoptosis In Vitro and Tumor Suppression In Vivo

Yang, D., Torres, C. M., Bardhan, K., Zimmerman, M. A., McGaha, T. L., & Liu, K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103035 · Cited by 83 · see citing works

Induction of MAGE-3 expression in lung and esophageal cancer cells

Weiser, T. S., Ohnmacht, G. A., Guo, Z. S., Fischette, M. R., Chen, G. A., Hong, J. A., Nguyen, D. M., & Schrump, D. S. (2001) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(00)02421-8 · Cited by 80 · see citing works

5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?

Sigalotti, L., Altomonte, M., Colizzi, F., Degan, M., Rupolo, M., Zagonel, V., Pinto, A., Gattei, V., & Maio, M. (2003) · Blood · doi:10.1182/blood-2002-11-3458 · Cited by 79 · see citing works

Inhibition of DNA Methylation by Antisense Oligonucleotide MG98 as Cancer Therapy

Amato, R. J. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.029 · Cited by 79 · see citing works

Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells

Gillenwater, A. M., Zhong, M., & Lotan, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0344 · Cited by 79 · see citing works

Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide

Coral, S., Parisi, G., Nicolay, H. J. M., Colizzi, F., Danielli, R., Fratta, E., Covre, A., Taverna, P., Sigalotti, L., & Maio, M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1365-7 · Cited by 76 · see citing works

Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis

Zhang, C., Wang, Y., Zhou, Z., Zhang, J., & Tian, Z. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0645-8 · Cited by 76 · see citing works

Transient Down-regulation of DNMT1 Methyltransferase Leads to Activation and Stable Hypomethylation of MAGE-A1 in Melanoma Cells

Loriot, A. E., Plaen, E. D., Boon, T., & Smet, C. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510469200 · Cited by 76 · see citing works

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

Ascierto, P. A., Marincola, F. M., & Ribas, A. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-196 · Cited by 76 · see citing works

Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway

Kim, H., Kim, E., Yang, S., Jeong, E., Park, C., Lee, J., Youn, M., So, H., & Park, R. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.73 · Cited by 74 · see citing works

Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid

Mora‐García, M. D. L., Dueñas‐González, A., Hernández‐Montes, J., la Cruz-Hernández, E. N. D., Pérez‐Cárdenas, E., Weiss‐Steider, B., Santiago‐Osorio, E., Ortiz-Navarrete, V. F., Rosales, V. H., de León, D. F. C., et al. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-55 · Cited by 72 · see citing works

Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells

Chou, S., Khan, A. N. H., Magner, W. J., & Tomasi, T. B. (2005) · International Immunology · doi:10.1093/intimm/dxh326 · Cited by 71 · see citing works

Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas

Setiadi, A., David, M. D., Seipp, R. P., Hartikainen, J. A., Gopaul, R., & Jefferies, W. A. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01547-07 · Cited by 71 · see citing works

Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas

Arnold, J. M., Cummings, M. C., Purdie, D., & Chenevix‐Trench, G. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2075 · Cited by 70 · see citing works

Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells

Schmudde, M., Braun, A., Pende, D., Sonnemann, J., Klier, U., Beck, J. F., Moretta, L., & Bröker, B. M. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.027 · Cited by 69 · see citing works

Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells

Sun, F., Chan, E., Wu, Z., Yang, X., Márquez, V. E., & Yu, Q. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0479 · Cited by 69 · see citing works

Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL

Bae, S., Cheriyath, V., Jacobs, B., Reu, F. J., & Borden, E. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210655 · Cited by 68 · see citing works

Down-Regulation of HLA Class I Antigens in Prostate Cancer Tissues and Up-Regulation by Histone Deacetylase Inhibition

Kitamura, H., Torigoe, T., Asanuma, H., Honma, I., Sato, N., & Tsukamoto, T. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.03.109 · Cited by 66 · see citing works

Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis

Berghuis, D., Schilham, M. W., Vos, H. I., Santos, S. J., Kloeß, S., Buddingh, E. P., Egeler, R. M., Hogendoorn, P. C. W., & Lankester, A. C. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-8 · Cited by 66 · see citing works

Hypermethylation of HLA class I gene is associated with HLA class I down‐regulation in human gastric cancer

Ye, Q., Shen, Y., Wang, X., Yang, J., Miao, F., Shen, C., & Zhang, J. (2009) · Tissue Antigens · doi:10.1111/j.1399-0039.2009.01390.x · Cited by 65 · see citing works

Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A

Gialitakis, M. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj462 · Cited by 65 · see citing works

Expression of RASSF1A, an Epigenetically Silenced Tumor Suppressor, Overcomes Resistance to Apoptosis Induction by Interferons

Reu, F. J., Leaman, D. W., Maitra, R. R., Bae, S. I., Cherkassky, L., Fox, M. W., Rempinski, D., Beaulieu, N., MacLeod, A. R., & Borden, E. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2303 · Cited by 65 · see citing works

NYESO-1/LAGE-1s and PRAME Are Targets for Antigen Specific T Cells in Chondrosarcoma following Treatment with 5-Aza-2-Deoxycitabine

Pollack, S. M., Li, Y., Blaisdell, M. J., Farrar, E. A., Chou, J., Hoch, B. L., Loggers, E. T., Rodler, E. T., Eary, J. F., Conrad, E. U., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032165 · Cited by 61 · see citing works

Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine

Tang, K., He, C., Zeng, G.-L., Wu, J., Song, G., Shi, Y., Zhang, W., Huang, A., Steinle, A., & Ren, H. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.131 · Cited by 61 · see citing works

Epigenetic Modulation of Solid Tumors as a Novel Approach for Cancer Immunotherapy

Sigalotti, L., Coral, S., Fratta, E., Lamaj, E., Danielli, R., Giacomo, A. M. D., Altomonte, M., & Maio, M. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.07.005 · Cited by 60 · see citing works

Distinct Roles for Histone Methyltransferases G9a and GLP in Cancer Germ-Line Antigen Gene Regulation in Human Cancer Cells and Murine Embryonic Stem Cells

Link, P. A., Gangisetty, O., James, S. R., Woloszynska‐Read, A., Tachibana, M., Shinkai, Y., & Karpf, A. R. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0497 · Cited by 59 · see citing works

Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status

Sigalotti, L., Covre, A., Zabierowski, S. E., Himes, B. T., Colizzi, F., Natali, P. G., Herlyn, M., & Maio, M. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21380 · Cited by 58 · see citing works

Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients

Sigalotti, L., Fratta, E., Bidoli, E., Covre, A., Parisi, G., Colizzi, F., Coral, S., Massarut, S., Kirkwood, J. M., & Maio, M. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-78 · Cited by 58 · see citing works

Post-Transcriptional and Epigenetic Regulation of Antigen Processing Machinery (APM) Components and HLA-I in Cervical Cancers from Uighur Women

Hasim, A., Abudula, M., Aimiduo, R., Ma, J., Jiao, Z., Akula, G., Wang, T., & Abudula, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044952 · Cited by 58 · see citing works

Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-γ in haematopoietic tumour cells

Morimoto, Y., Toyota, M., Satoh, A., Murai, M., Mita, H., Suzuki, H., Takamura, Y., Ikeda, H., Ishida, T., Sato, N., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601602 · Cited by 53 · see citing works

The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.

Höring, E., Podlech, O., Silkenstedt, B., Rota, I. A., Adamopoulou, E., & Naumann, U. (2013) · PubMed · Cited by 52 · see citing works

Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma

Procopio, A. D., Strizzi, L., Vianale, G., Betta, P., Puntoni, R., Fontana, V., Tassi, G., Gareri, F., & Mutti, L. (2000) · Genes Chromosomes and Cancer · doi:10.1002/1098-2264(2000)9999:9999 · Cited by 52 · see citing works

Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate

Due�as-Gonz�lez, A. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1144 · Cited by 50 · see citing works

Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity

Yamanegi (2010) · Oncology Reports · doi:10.3892/or_00001026 · Cited by 49 · see citing works

Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications

Coral, S., Sigalotti, L., Colizzi, F., Spessotto, A., Nardi, G., Cortini, E., Pezzani, L., Fratta, E., Fonsatti, E., Giacomo, A. M. D., et al. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20540 · Cited by 48 · see citing works

Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer

Chou, J., Voong, L. N., Mortales, C., Towlerton, A. M. H., Pollack, S. M., Chen, X., Yee, C., Robbins, P. F., & Warren, E. H. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31824300c7 · Cited by 48 · see citing works

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes

Godley, L. A., García, & Jain (2010) · OncoTargets and Therapy · doi:10.2147/ott.s7222 · Cited by 47 · see citing works

Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status

Šímová, J., Polláková, V., Indrová, M., Mikyšková, R., Bieblová, J., Štěpánek, I., Bubenik, J., & Reiniš, M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.428 · Cited by 47 · see citing works

Methylation‐regulated expression of HLA class I antigens in melanoma

Fonsatti, E., Sigalotti, L., Coral, S., Colizzi, F., Altomonte, M., & Maio, M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11077 · Cited by 45 · see citing works

Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells

Luo, W., Wang, X., Kageshita, T., Wakasugi, S., Karpf, A. R., & Ferrone, S. (2005) · Oncogene · doi:10.1038/sj.onc.1209319 · Cited by 45 · see citing works

Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.

Kozar, K., Kamiński, R., Świtaj, T., Ołdak, T., Machaj, E. K., Wysocki, P. J., Mackiewicz, A. A., Lasek, W., Jakóbisiak, M., & Gołąb, J. (2003) · PubMed · Cited by 45 · see citing works

DNA Demethylating Antineoplastic Strategies: A Comparative Point of View

Amatori, S., Bagaloni, I., Donati, B., & Fanelli, M. (2010) · Genes & Cancer · doi:10.1177/1947601910365081 · Cited by 45 · see citing works

CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893

Kalbasi, A. K., Fonsatti, E., Natali, P. G., Altomonte, M., Bertocci, E., Cutaia, O., Calabrò, L., Chiou, M., Tap, W. D., Chmielowski, B., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee73a7 · Cited by 45 · see citing works

Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway

Konkankit, V., Kim, W. B., Koya, R. C., Eskin, A., Dam, M.-A., Nelson, S. F., Ribas, A., Liau, L. M., & Prins, R. M. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-192 · Cited by 44 · see citing works

Histone Deacetylation, But Not Hypermethylation, Modifies Class II Transactivator and MHC Class II Gene Expression in Squamous Cell Carcinomas

Kanaseki, T., Ikeda, H., Takamura, Y., Toyota, M., Hirohashi, Y., Tokino, T., Himi, T., & Sato, N. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4980 · Cited by 43 · see citing works

Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4

Scherf, D. B., Sarkisyan, N., Jacobsson, H., Claus, R., Bermejo, J. L., Peil, B., Gu, L., Muley, T., Meister, M. A., Dienemann, H., et al. (2012) · Oncogene · doi:10.1038/onc.2012.344 · Cited by 43 · see citing works

Emerging Anticancer Therapeutic Targets and the Cardiovascular System

Peng, X., Pentassuglia, L., & Sawyer, D. B. (2010) · Circulation Research · doi:10.1161/circresaha.109.211276 · Cited by 39 · see citing works

Epigenetic events in tumorigenesis: putting the pieces together.

Pogribny, I. P. (2010) · PubMed · Cited by 39 · see citing works

Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics

Qifeng, S., Bo, C., Xingtao, J., Chuanliang, P., & Zhao, X. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2010.04.031 · Cited by 35 · see citing works

Loss of imprinting of igf2 in renal-cell carcinomas

Oda, H., Kume, H., Shimizu, Y., Inoue, T., & Ishikawa, T. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980130)75:3 · Cited by 33 · see citing works

Effect of the histone deacetylase inhibitor SNDX‐275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases

Koshkina, N. V., Rao‐Bindal, K., & Kleinerman, E. S. (2011) · Cancer · doi:10.1002/cncr.25884 · Cited by 31 · see citing works

CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells

Londhe, P., Zhu, B., Abraham, J., Keller, C., & Davie, J. K. (2011) · International Journal of Cancer · doi:10.1002/ijc.26478 · Cited by 30 · see citing works

MAGE‐A10 cancer/testis antigen is highly expressed in high‐grade non‐muscle‐invasive bladder carcinomas

Mengus, C., Schultz‐Thater, E., Coulot, J., Kaštelan, Ž., Goluža, E., Ćorić, M., Spagnoli, G. C., & Hudolin, T. (2012) · International Journal of Cancer · doi:10.1002/ijc.27914 · Cited by 30 · see citing works

Different levels of control prevent interferon-γ-inducible HLA-class II expression in human neuroblastoma cells

Croce, M., Ambrosis, A. D., Corrias, M. V., Pistoia, V., Occhino, M., Meazza, R., Giron‐Michel, J., Azzarone, B. G., Accolla, R. S., & Ferrini, S. (2003) · Oncogene · doi:10.1038/sj.onc.1207054 · Cited by 29 · see citing works

Loss of interferon-γ inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation

Meißner, M., Whiteside, T. L., van Kuik‐Romeijn, P., Valesky, E. M., van den Elsen, P. J., Kaufmann, R., & Seliger, B. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08465.x · Cited by 29 · see citing works

MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts

Rao‐Bindal, K., Zhou, Z., & Kleinerman, E. S. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.101 · Cited by 28 · see citing works

Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome

Jiang, Q., Pan, H., Ye, D., Zhang, P., Zhong, L., & Zhang, Z. (2010) · Tumor Biology · doi:10.1007/s13277-010-0054-4 · Cited by 27 · see citing works

Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death

Yamanegi, K. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1438 · Cited by 27 · see citing works

Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity

Lech‐Marańda, E., Robak, E., Korycka, A., & Robak, T. (2007) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707782110178 · Cited by 26 · see citing works

Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator

Radosevich, M., Jager, M. J., & Ono, S. J. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2006.03.005 · Cited by 25 · see citing works

Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications

Coral, S., Covre, A., Nicolay, H. J. M., Parisi, G., Rizzo, A., Colizzi, F., Santa, S. D., Fonsatti, E., Fratta, E., Sigalotti, L., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.361 · Cited by 25 · see citing works

5-AZA-2′-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story

Coral, S., Sigalotti, L., Covre, A., Nicolay, H. J. M., Natali, P. G., & Maio, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2986 · Cited by 23 · see citing works

Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma

Fratta, E., Sigalotti, L., Colizzi, F., Covre, A., Nicolay, H. J. M., Danielli, R., Fonsatti, E., Altomonte, M., Calabrò, L., Coral, S., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22040 · Cited by 21 · see citing works

Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.

Jazirehi, A. R., & Arle, D. (2013) · PubMed · Cited by 20 · see citing works

LMP gene promoter hypermethylation is a mechanism for its down regulation in Kazak’s esophageal squamous cell carcinomas

Zheng, F., Hasim, A., Anwer, J., Niyaz, M., & Sheyhidin, I. (2013) · Molecular Biology Reports · doi:10.1007/s11033-012-2138-2 · Cited by 10 · see citing works

Epigenetically regulated tumor-associated antigens in melanoma

Nicolay, H. J. M., Sigalotti, L., Fonsatti, E., Covre, A., Parisi, G., Fratta, E., Coral, S., & Maio, M. (2009) · Expert Review of Dermatology · doi:10.1586/edm.09.6 · Cited by 1 · see citing works

The roles of DNA, RNA and histone methylation in ageing and cancer

Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549 · see citing works

Immune checkpoint therapy in liver cancer

Xu, F., Jin, T., Zhu, Y., & Dai, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0777-4 · Cited by 398 · see citing works

The cancer epigenome: Concepts, challenges, and therapeutic opportunities

Dawson, M. A. (2017) · Science · doi:10.1126/science.aam7304 · Cited by 377 · see citing works

Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy

Phuengkham, H., Ren, L. F., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 304 · see citing works

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02630-w · Cited by 275 · see citing works

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

Li, Q., Han, J., Yang, Y., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070961 · Cited by 252 · see citing works

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker

Wang, Z., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3410 · Cited by 200 · see citing works

Epigenetics and immunotherapy: The current state of play

Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 189 · see citing works

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

Bai, J., Gao, Z., Li, X., Dong, L., Han, W., & Nie, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22690 · Cited by 157 · see citing works

DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer

Nair, V. S., Salhat, H. E., Taha, R. Z., John, A., Ali, B. R., & Elkord, E. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0512-1 · Cited by 153 · see citing works

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells

Gameiro, S. R., Malamas, A. S., Tsang, K. Y., Ferrone, S., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.7180 · Cited by 108 · see citing works

Combinatorial approach to cancer immunotherapy: strength in numbers

Vilgelm, A. E., Johnson, D. B., & Richmond, A. J. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 106 · see citing works

Role of Methylation in Pro- and Anti-Cancer Immunity

Mehdi, A., & Rabbani, S. A. (2021) · Cancers · doi:10.3390/cancers13030545 · Cited by 102 · see citing works

Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy

Maio, M., Covre, A., Fratta, E., Giacomo, A. M. D., Taverna, P., Natali, P. G., Coral, S., & Sigalotti, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2914 · Cited by 100 · see citing works

Epigenetics in Cancer: A Hematological Perspective

Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 90 · see citing works

HDAC inhibitors as epigenetic regulators for cancer immunotherapy

Conte, M., Palma, R. D., & Altucci, L. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.03.004 · Cited by 90 · see citing works

A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy

Liu, Z., Ren, Y., Weng, S., Xu, H., Li, L., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.809761 · Cited by 89 · see citing works

Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

Giacomo, A. M. D., Covre, A., Finotello, F., Rieder, D., Danielli, R., Sigalotti, L., Giannarelli, D., Petitprez, F., Lacroix, L., Valente, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1335 · Cited by 84 · see citing works

DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses

Dan, H., Zhang, S., Zhou, Y., & Guan, Q. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217767 · Cited by 81 · see citing works

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

Robert, L., Ribas, A., & Hu‐Lieskovan, S. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.01.001 · Cited by 72 · see citing works

Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models

Covre, A., Coral, S., Nicolay, H. J. M., Parisi, G., Fazio, C., Colizzi, F., Fratta, E., Giacomo, A. M. D., Sigalotti, L., Natali, P. G., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1019978 · Cited by 71 · see citing works

Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy

Liu, M., Zhou, J., Chen, Z., & Cheng, A. S. L. (2016) · The Journal of Pathology · doi:10.1002/path.4832 · Cited by 71 · see citing works

Regulation of antitumor immunity by inflammation-induced epigenetic alterations

Karin, M., & Shalapour, S. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00756-y · Cited by 66 · see citing works

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment

Criscuolo, D., Morra, F., Giannella, R., Visconti, R., Cerrato, A., & Celetti, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1089-z · Cited by 64 · see citing works

Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy

Prabhakaran, R., Thamarai, R., Sivasamy, S., Dhandayuthapani, S., Batra, J., Kamaraj, C., Karthik, K., Shah, M. A., & Mallik, S. (2024) · Epigenetics & Chromatin · doi:10.1186/s13072-024-00554-6 · Cited by 67 · see citing works

Cancer immunotherapy

Dhar, R., Seethy, A. A., Singh, S., Pethusamy, K., Srivastava, T. P., Talukdar, J., Rath, G. K., & Karmakar, S. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1241_20 · Cited by 59 · see citing works

Novel Combination Therapies for the Treatment of Bladder Cancer

Peng, M., Xiao, D., Bu, Y., Long, J., Yang, X., Lv, S., & Yang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.539527 · Cited by 54 · see citing works

Potential of epigenetic therapies in the management of solid tumors

Valdespino, V., & Valdespino-Castillo, P. M. (2015) · Cancer Management and Research · doi:10.2147/cmar.s70358 · Cited by 53 · see citing works

Interplay Between Inflammation and Epigenetic Changes in Cancer

Maiuri, A. R., & O’Hagan, H. M. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.09.002 · Cited by 50 · see citing works

Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors

Liang, Y. J., Wang, L., Ma, P., Ju, D., Zhao, M., & Shi, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1308264 · Cited by 42 · see citing works

Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications

Ma, C., Cheng, J., Gu, J. H., & Wang, Q. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00373-5 · Cited by 42 · see citing works

Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation

Barrio‐Real, L., Benedetti, L. G., Engel, N., Tu, Y., Cho, S., Sukumar, S. V., & Kazanietz, M. G. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0441-7 · Cited by 41 · see citing works

New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry

Maryamchik, E., Gallagher, K., Preffer, F. I., Kadauke, S., & Maus, M. V. (2020) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21880 · Cited by 41 · see citing works

Decitabine: a promising epi-immunotherapeutic agent in solid tumors

Li, X., Mei, Q., Nie, J., Fu, X., & Han, W. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1002397 · Cited by 39 · see citing works

DNA Methylation–Targeted Drugs

Costa, E. M. D., McInnes, G., Beaudry, A., & Raynal, N. J. ‐. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000278 · Cited by 39 · see citing works

The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1α Stability and Angiogenesis

Oh, S. Y., Seok, J., Choi, Y. S., Lee, S. H., Bae, J.-S., & Lee, Y. M. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0026 · Cited by 36 · see citing works

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02628-x · Cited by 35 · see citing works

Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy

Fazio, C., Covre, A., Cutaia, O., Lofiego, M. F., Tunici, P., Chiarucci, C., Cannito, S., Giacobini, G., Lowder, J. N., Ferraldeschi, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01443 · Cited by 35 · see citing works

Molecular mechanisms underlying eicosapentaenoic acid inhibition of HDAC1 and DNMT expression and activity in carcinoma cells

Ceccarelli, V., Ronchetti, S., Marchetti, M. C., Calvitti, M., Riccardi, C., Grignani, F., & Vecchini, A. (2020) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2020.194481 · Cited by 34 · see citing works

Cancer Stem Cells: Devil or Savior—Looking behind the Scenes of Immunotherapy Failure

Castagnoli, L., Santis, F. D., Volpari, T., Vernieri, C., Tagliabue, E., Nicola, M. D., & Pupa, S. M. (2020) · Cells · doi:10.3390/cells9030555 · Cited by 33 · see citing works

Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity

Wachowska, M., Muchowicz, A., & Gołąb, J. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00176 · Cited by 32 · see citing works

Epigenetics Meets Immune Checkpoints

Covre, A., Coral, S., Giacomo, A. M. D., Taverna, P., Azab, M., & Maio, M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.003 · Cited by 31 · see citing works

IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer

Buoncervello, M., Romagnoli, G., Buccarelli, M., Fragale, A., Toschi, E., Parlato, S., Lucchetti, D., Macchia, D., Spada, M., Canini, I., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8379 · Cited by 31 · see citing works

Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression

Natoli, M., Gallon, J., Lu, H., Amgheib, A., Pinato, D. J., Mauri, F. A., Marafioti, T., Akarca, A. U., Ullmo, I., Ip, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001519 · Cited by 31 · see citing works

Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue?

Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2019) · Cancer · doi:10.1002/cncr.32041 · Cited by 30 · see citing works

Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells

Dockry, É., O’Leary, S. M., Gleeson, L. E., Lyons, J., Keane, J., Gray, S. G., & Doherty, D. G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1428156 · Cited by 29 · see citing works

Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors

Liu, Z., Gao, Y., & Li, X. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1552139 · Cited by 27 · see citing works

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment

Liu, Z.-L., Liu, J., Staiculescu, D., & Chen, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018026 · Cited by 24 · see citing works

The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy

Mokhtari, R. B., Sambi, M., Qorri, B., Baluch, N., Ashayeri, N., Kumar, S., Cheng, H. M., Yeger, H., Das, B., & Szewczuk, M. R. (2021) · Cancers · doi:10.3390/cancers13143596 · Cited by 25 · see citing works

Genome-Wide Demethylation by 5-aza-2’-Deoxycytidine Alters the Cell Fate of Stem/Progenitor Cells

Zhou, Y., & Hu, Z. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-014-9542-z · Cited by 24 · see citing works

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

Calabrò, L., Ceresoli, G. L., di Pietro, A., Cutaia, O., Morra, A., Ibrahim, R. A., & Maio, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1609-9 · Cited by 21 · see citing works

Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy

Lu, F., Hou, L., Wang, S., Yu, Y., Zhang, Y., Sun, L., Wang, C., Ma, Z., & Yang, F. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1927246 · Cited by 21 · see citing works

Epi-drugs as triple-negative breast cancer treatment

Idrissou, M., Sánchez, A., Penault-Llorca, F. M., Bignon, Y., & Bernard-Gallon, D. J. (2020) · Epigenomics · doi:10.2217/epi-2019-0312 · Cited by 20 · see citing works

Tumor immunotherapy—the potential of epigenetic drugs to overcome resistance

Grunewald, C. M., Schulz, W. A., Skowron, M. A., Hoffmann, M. J., & Niegisch, G. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.06.24 · Cited by 18 · see citing works

Genetics and Epigenetics of Glioblastoma: Therapeutic Challenges

Zayeri, Z. D., Rasras, S., Zibara, K., & Vosughi, T. (2018) · Clinical Cancer Investigation Journal · doi:10.4103/ccij.ccij_82_17 · Cited by 17 · see citing works

Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy

Kishi, M., Asgarova, A., Desterke, C., Chaker, D., Artus, J., Turhan, A. G., Griscelli, A. B., & Griscelli, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.729018 · Cited by 17 · see citing works

Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma

Morante, M., Pandiella, A., Crespo, P., & Herrero, A. (2022) · Biomolecules · doi:10.3390/biom12111562 · Cited by 17 · see citing works

Where does PD-1 blockade fit in HL therapy?

Herrera, A. F. (2018) · Hematology · doi:10.1182/asheducation-2018.1.213 · Cited by 15 · see citing works

Epigenome-Driven Strategies for Personalized Cancer Immunotherapy

Rocha, G. I. Y., Gomes, J. E. M., Leite, M. L., da Cunha, N. B., & Costa, F. F. (2023) · Cancer Management and Research · doi:10.2147/cmar.s272031 · Cited by 13 · see citing works

Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer

Cho, J. H., Öezkan, F., Koenig, M. J., Otterson, G. A., Herman, J. G., & He, K. (2017) · Current Pharmacology Reports · doi:10.1007/s40495-017-0110-5 · Cited by 14 · see citing works

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents

Oronsky, B. T., Scicinski, J. J., Kim, M. M., Cabrales, P., Salacz, M. E., Carter, C. A., Oronsky, N. C., Lybeck, H., Lybeck, M., Larson, C., et al. (2016) · Biomolecules · doi:10.3390/biom6030032 · Cited by 11 · see citing works

Integrated analysis from multicentre studies identities m7G-related lncRNA-derived molecular subtypes and risk stratification systems for gastric cancer

Ma, M., Li, J., Zeng, Z., Zheng, Z., & Kang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1096488 · Cited by 11 · see citing works

NUC041, a Prodrug of the DNA Methytransferase Inhibitor 5-aza-2′,2′-Difluorodeoxycytidine (NUC013), Leads to Tumor Regression in a Model of Non-Small Cell Lung Cancer

Daifuku, R., Grimes, S. D., & Stackhouse, M. A. (2018) · Pharmaceuticals · doi:10.3390/ph11020036 · Cited by 10 · see citing works

Gelated Vorinostat with inner-lysosome triggered release for tumor-targeting chemotherapy

Guo, C., Wang, Q., Zhang, X., Lu, F., Sun, M., Zeng, P., Sun, L., She, L., Wang, B., Zhang, Y., et al. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111144 · Cited by 10 · see citing works

Mechanism of resistance to immune checkpoint inhibitors

Pandey, M. R., & Ernstoff, M. S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.015 · Cited by 9 · see citing works

Unleashing precision: A review of targeted approaches in pleural mesothelioma

Occhipinti, M. A., Brambilla, M., Liello, R. D., Ambrosini, P., Lobianco, L., Leporati, R., Salvarezza, M., Vitiello, F., Marchesi, S., Manglaviti, S., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104481 · Cited by 9 · see citing works

Genome-Wide Microarray Expression and Genomic Alterations by Array-CGH Analysis in Neuroblastoma Stem-Like Cells

Ordóñez, R., Gallo-Oller, G., Martínez-Soto, S., Legarra, S., Pata-Merci, N., Guégan, J., Danglot, G., Bernheim, A., Meléndez, B., REY, J. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113105 · Cited by 9 · see citing works

Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker

Zhao, C., Liu, Y., Ju, S., & Wang, X. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s331752 · Cited by 9 · see citing works

Epigenetic mechanisms of liver tumor resistance to immunotherapy

Sanceau, J., & Gougèlet, A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.979 · Cited by 9 · see citing works

Discovery and Development of HDAC Subtype Selective Inhibitor Chidamide: Potential Immunomodulatory Activity Against Cancers

Lu, X., Ning, Z., Li, Z., Pan, D., Shan, S., Guo, X., Cao, H., Yu, J., & Yang, Q. (2016) · doi:10.1002/9783527800315.ch5 · Cited by 9 · see citing works

Advancement in hepatocellular carcinoma research: Biomarkers, therapeutics approaches and impact of artificial intelligence

Rajak, D., Nema, P., Sahu, A., Vishwakarma, S., & Kashaw, S. K. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111120 · Cited by 8 · see citing works

Rewiring the solid tumor epigenome for cancer therapy

Braun, C. J., & Hemann, M. T. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1212663 · Cited by 8 · see citing works

Pharmacoepigenetics of Novel Nucleoside DNA Methyltransferase Inhibitors

Daifuku, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00007-3 · Cited by 8 · see citing works

To Identify Adenomatous Polyposis Coli Gene Mutation as a Predictive Marker of Endometrial Cancer Immunotherapy

Song, Y., Huang, J. H., Wang, K., & Li, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.935650 · Cited by 7 · see citing works

Adenosine Kinase on Deoxyribonucleic Acid Methylation: Adenosine Receptor-Independent Pathway in Cancer Therapy

Luo, H., Shen, H., Perkins, R. S., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.908882 · Cited by 7 · see citing works

Polymerized vorinostat mediated photodynamic therapy using lysosomal spatiotemporal synchronized drug release complex

Hu, P., Sun, M., Lu, F., Wang, S., Hou, L., Yu, Y., Zhang, Y., Sun, L., Yao, J., Yang, F., et al. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111903 · Cited by 6 · see citing works

Role of Immune Cell-Specific Hypermethylation Signatures in Classification and Risk Stratification of Breast Cancer

Chen, Y., Xia, F., Jiang, B., Wang, W., & Li, X. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.674338 · Cited by 5 · see citing works

Analysis of m7G-Related signatures in the tumour immune microenvironment and identification of clinical prognostic regulators in breast cancer

Huang, Q., Mo, J., Yang, H., Ji, Y., Huang, R. H., Liu, Y., & You, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-11012-z · Cited by 5 · see citing works

Chromatin Memory in the Development of Human Cancers

Yao, Y. (2014) · Gene Technology · doi:10.4172/2329-6682.1000114 · Cited by 4 · see citing works

It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective

Zaalberg, A., Pottendorfer, E., Zwart, W. T., & Bergman, A. M. (2024) · Cancers · doi:10.3390/cancers16020294 · Cited by 3 · see citing works

Effect of Trichostatin A on CNE2 Nasopharyngeal Carcinoma Cells - Genome-wide DNA Methylation Alteration

Yang, X., Zhang, C., Wu, H., Wu, Y., Zhang, Y.-N., Qin, M., Wu, H., Liu, X., Lina, X., & Lu, S. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.11.4663 · Cited by 3 · see citing works

Epigenetics and Immunotherapy: New Perspective for Breaking Chronic Viral Infection

Yan, J. (2016) · Immunotherapy Open Access · doi:10.4172/2471-9552.1000106 · Cited by 2 · see citing works

Combining Epigenetic and Immunotherapy in Cancer: Molecular Mechanisms

Meiliana, A., & Wijaya, A. (2023) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v15i1.2062 · Cited by 1 · see citing works

Efficacy of Combined Epigenetic Therapies

Raynal, N. J. ‐. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802208-5.00014-x · Cited by 1 · see citing works

Senescence Induced by DNA Demethylating Drugs to Treat Solid Tumors

Jueliger, S., Taverna, P., Re, O. L., & Vinciguerra, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-64597-1_166-1 · Cited by 1 · see citing works

Targeting Epigenetic Regulators in Cancer to Overcome Targeted Therapy Resistance

Raz, D. J. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_11 · Cited by 1 · see citing works

Senescence Induced by DNA Demethylating Drugs to Treat Solid Tumors

Jueliger, S., Taverna, P., Re, O. L., & Vinciguerra, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_166 · Cited by 1 · see citing works

The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology

Giacomo, A. M. D., Covre, A., Giacobini, G., Ibrahim, R. A., Lyman, J. P., Natali, P. G., & Maio, M. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2286-x · Cited by 1 · see citing works

Molecular/Targeted Therapy of Cancer

Vail, D. M., Thamm, D. H., & Liptak, J. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-59496-7.00015-3 · Cited by 1 · see citing works

Cancer Epigenomics on Precision Medicine and Immunotherapy

Orozco, J. I. J., Marzese, D. M., & Hoon, D. S. �. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_68-1

THE STUDY OF ANTITUMOR ACTIVITY OF PHENYLBUTYRATE IN COMBINATION WITH 5-FLUOROURACIL ON MODEL OF EHRLICH CARCINOMA

Фадеев, Н. П., Kharisov, R. I., Eg, K., Пустовалов, Ю. И., & Fadeeva, V. L. (2017) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2017-16-1-70-75

Clinical utility of solid tumor epigenetics

Demirdizen, E., Taranda, J., & Turcan, Ş. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00013-x

Cancer Epigenomics on Precision Medicine and Immunotherapy

Orozco, J. I. J., Marzese, D. M., & Hoon, D. S. �. (2019) · Springer eBooks · doi:10.1007/978-3-319-55530-0_68

Epigenetic Drugs as Modulators of Tumor Immunogenicity and Host Immune Response

Marchi, E., Pal, I., Manavalan, J. S., Jayappa, K. D., & O’Connor, O. A. (2024) · doi:10.1002/9781119824572.ch28

Pharmacoepigenetics of novel nucleoside DNA methyltransferase inhibitors

Daifuku, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00001-3

Additional file 1 of Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22621855

Additional file 4 of Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22621864

Additional file 3 of Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22621861

Additional file 5 of Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22621867

Additional file 2 of Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Amaro, A. A., Reggiani, F., Fenoglio, D., Gangemi, R. M. R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22621858

Epigenetic Modulation of Solid Tumors as a Novel Approach for Cancer Immunotherapy

Sigalotti, L., Coral, S., Fratta, E., Lamaj, E., Danielli, R., Giacomo, A. M. D., Altomonte, M., & Maio, M. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.07.005 · Cited by 60 · see citing works

Epigenetics and immunotherapy: The current state of play

Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 189 · see citing works

Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential

Maes, K., Mondino, A., Lasarte, J. J., Agirre, X., Vanderkerken, K., Prósper, F., & Breckpot, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652160 · Cited by 25 · see citing works

Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy

Maio, M., Covre, A., Fratta, E., Giacomo, A. M. D., Taverna, P., Natali, P. G., Coral, S., & Sigalotti, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2914 · Cited by 100 · see citing works

Epigenetic targets for immune intervention in human malignancies

Maio, M., Coral, S., Fratta, E., Altomonte, M., & Sigalotti, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206956 · Cited by 71 · see citing works